(NASDAQ: TMDX) Transmedics Group's forecast annual revenue growth rate of 18.33% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.04%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Transmedics Group's revenue in 2025 is $441,540,000.On average, 5 Wall Street analysts forecast TMDX's revenue for 2025 to be $18,311,382,926, with the lowest TMDX revenue forecast at $18,079,718,544, and the highest TMDX revenue forecast at $18,692,710,174. On average, 5 Wall Street analysts forecast TMDX's revenue for 2026 to be $22,209,753,860, with the lowest TMDX revenue forecast at $21,483,656,690, and the highest TMDX revenue forecast at $23,109,212,200.
In 2027, TMDX is forecast to generate $23,889,640,423 in revenue, with the lowest revenue forecast at $23,845,408,078 and the highest revenue forecast at $23,933,872,768.